New EMA guidance to stress role of biology in cancer drug development
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is planning to update its guidance on evaluating anticancer drugs to take account of the increase in the growing number and increasing diversity of new substances being developed and the need to identify those patients most likely to respond to a particular product.